Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab in Early Peripheral Spondyloarthritis
NCT01426815Phase 3Completed
- Sponsor
- Ghent University Hospital
- Start
- Mar 2012
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in peripheral spondyloarthritis (pSpA) comparing Golimumab with Placebo (2 arms). Primary endpoint: Clinical remission at 24 weeks. Started Mar 2012; status: completed.
02
Drugs
golimumab
03
Conditions
peripheral spondyloarthritis (pSpA)
Beyond the preview
Go deeper on NCT01426815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01426815.